Biotech company BioSenic (Euronext Brussels/Paris:BIOS) said on Wednesday that it has signed a term sheet with Pluristyx, a provider of gene-edited iPSC and cell therapy solutions, paving the way for a potential licence and collaboration agreement.

The term sheet will serve as the basis for a wider agreement that aims to make BioSenic's ALLOB mesenchymal cells -- with various properties, including immune privilege, anti-inflammatory capabilities and tissue repair abilities -- available to the market. Derived from Mesenchymal Stem Cells (MSCs), these cells are part of BioSenic's investigational medicinal product, ALLOB, which is currently being evaluated in a Phase IIb study.

BioSenic and Pluristyx will negotiate the terms and conditions, with a goal to finalise and execute the agreement by Q3 2023, subject to customary conditions.

The potential agreement would enable BioSenic to prepare the cells for market availability for preclinical research and possible clinical applications. Pluristyx specialises in partnerships with companies and research institutions to create and commercialise new therapies and offer services to clients who need support with their own cell therapy development, manufacturing and/or regulatory compliance.

As part of the agreement, BioSenic would grant Pluristyx a conditional non-exclusive licence to exploit ALLOB, including the production and sale of immortalised ALLOB cells and the generation of a Cell Bank.